# Evaluation of the Safety and Efficacy of a Monoclonal Antibody to Treat Influenza

> **NCT03903718** · PHASE2 · WITHDRAWN · sponsor: **MedImmune LLC**

## Conditions studied

- Influenza

## Interventions

- **DRUG:** Oseltamivir
- **BIOLOGICAL:** MEDI8852
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03903718
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-04-03
- **Primary completion:** 2020-10-09
- **Final completion:** 2020-10-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Terminated due to delay in site enrollment timelines
- **Last updated:** 2020-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03903718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03903718, "Evaluation of the Safety and Efficacy of a Monoclonal Antibody to Treat Influenza". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03903718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*